Accessibility Menu
PolyNovo logo

PolyNovo(OTC) CALZF

Current Price$0.59
Market Cap$407.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-16%
5 Year-65%
1 Year-31%
1 Month-5%
PolyNovo last closing stock price
MetricPriceDate
Last closeUSD 0.592026-07-24
PolyNovo stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-13.3%USD 0.682026-07-17
1 month-4.84%USD 0.622026-06-24
3 month-20.27%USD 0.742026-04-20
Year to date-24.37%USD 0.782025-12-31
1 year-30.99%USD 0.862025-07-24
3 year-43.81%USD 1.052023-07-19
5 year-65.29%USD 1.702021-07-20
Since inception-15.71%USD 0.702003-08-08

PolyNovo Financials at a Glance

Market Cap

$407.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$253.48M

Net Income (TTM)

A$15.78M

EPS (TTM)

$0.01

P/E Ratio

64.84

Dividend

$0.00

Beta (Volatility)

-19380.63 (Low)

Price

$0.59

Volume

5,008

Open

$0.59

Previous Close

$0.59

Daily Range

$0.59 - $0.59

52-Week Range

$0.59 - $1.02

Estimated Earnings Date

Aug 21, 2026

CALZF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PolyNovo

Polynovo Limited is a biotechnology company focused on developing innovative medical devices using its patented polymer technology, NovoSorb. The company specializes in biodegradable temporizing matrix (BTM) products, which are designed to improve patient outcomes in wound care and surgical applications.

Products and Services
  • Biodegradable temporizing matrix (BTM) for wound care
  • Advanced polymer technology for medical applications
  • Products aimed at enhancing surgical recovery
Growth Outlook
  • Revenue increased to AUD 70.17 million in the latest quarter
  • Gross profit margin improved to 30.57% in Q2 2025
  • Strong demand for innovative wound care solutions drives market expansion
Financial Highlights
  • Net income of AUD 2,998 in Q2 2025, showing profitability
  • Current ratio of 3.03 indicates strong liquidity position
  • Trailing twelve months (TTM) revenue of AUD 246.5 million reflects consistent growth
Polynovo Limited operates primarily in the United States, Australia, New Zealand, and other countries, positioning itself as a key player in the healthcare sector. The company's focus on innovative solutions in wound care is supported by its strong financial performance, as evidenced by the recent quarterly revenue growth and improved gross profit margins. The current ratio indicates a solid liquidity position, allowing for potential reinvestment in research and development. With a growing demand for advanced medical solutions, Polynovo is well-positioned to capitalize on market opportunities and enhance shareholder value.
AI Generated • Jul 16, 2026

Industry

Healthcare Equipment and Supplies

Employees

301

CEO

Robyn Elliott, PhD

Headquarters

Port Melbourne, VIC 3207, AU

CALZF Financials

Key Financial Metrics (TTM)

Gross Margin

32.31%

Operating Margin

1.98%

Net Income Margin

7.16%

Return on Equity

11.87%

Return on Capital

4.47%

Return on Assets

8.01%

Earnings Yield

1.54%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$407.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

690.84M

Volume

5.01K

Avg. Volume

2.63K

Financials (TTM)

Gross Profit

A$117.39M

Operating Income

A$6.12M

EBITDA

A$16.50M

Operating Cash Flow

A$15.51M

Capital Expenditure

-A$26.49M

Free Cash Flow

-A$10.98M

Cash & ST Invst.

A$29.25M

Total Debt

A$31.73M

PolyNovo Performance Analysis

PolyNovo annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 30,055,725N/A
20232023-06-30AUD 43,888,23146.0%
20242024-06-30AUD 67,629,45954.1%
20252025-06-30AUD 82,406,51021.9%
PolyNovo sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3018.9%
Q22024-12-316.2%
Q42025-06-3013.8%
Q22025-12-313.6%
PolyNovo annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.00N/A
20232023-06-30AUD -0.00269.2%
20242024-06-30AUD 0.00N/A
20252025-06-30AUD 0.01153.1%
PolyNovo sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-5.1%
Q22024-12-3129.7%
Q42025-06-30197.9%
Q22025-12-31-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$70.17M

+48.8%

Gross Profit

A$21.45M

+29.2%

Gross Margin

30.57%

N/A

Market Cap

$407.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.35M

N/A

Employees

301

N/A

Net Income

A$3.00K

-99.9%

EBITDA

A$3.35M

+34.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$29.25M

-35.9%

Total Debt

A$31.73M

+106.9%

Accounts Receivable

A$24.20M

+70.8%

Inventory

A$11.85M

+72.0%

Long Term Debt

A$28.93M

+111.2%

Short Term Debt

A$2.80M

+71.1%

Return on Assets

8.01%

N/A

Return on Invested Capital

2.72%

N/A

Free Cash Flow

-A$1.62M

-3406.9%

Operating Cash Flow

A$9.15M

+688.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLVSFCellaVision AB (publ)
$14.00+0.00%
SOLTFNxera Pharma Co., Ltd.
$5.63+0.00%
BOIRFBoiron S.A.
$31.50+0.00%
AVNBFAvon Technologies Plc
$22.49+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About CALZF

What is the current price of PolyNovo?

PolyNovo is trading at $0.59 per share.

What is the 52-week range for PolyNovo?

Over the past 52 weeks, PolyNovo has traded between $0.59 and $1.02.

How much debt does PolyNovo have?

As of the most recent reporting period, PolyNovo reported total debt of A$11.23M.

How much cash does PolyNovo have on hand?

PolyNovo reported A$21.98M in cash and cash equivalents in its most recent financial results.

What is PolyNovo’s dividend yield?

PolyNovo does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.